Comparative Pharmacology
Head-to-head clinical analysis: STILPHOSTROL versus THEELIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: STILPHOSTROL versus THEELIN.
STILPHOSTROL vs THEELIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen; binds to estrogen receptors, inducing tumor regression in hormone-sensitive cancers.
Estrogen receptor agonist; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and promoting estrogenic effects.
0.5-1 mg/kg intravenously daily for 5 days, then 0.5 mg/kg intramuscularly weekly.
Intramuscular: 0.22 to 1.1 mg (220 to 1100 mcg) once weekly for menopausal symptoms; 0.5 to 2 mg (500 to 2000 mcg) once weekly for prostatic carcinoma.
None Documented
None Documented
Terminal elimination half-life: 50-60 hours (range 40-80 hr) due to enterohepatic recirculation; clinical context: steady-state achieved in ~10-14 days
Terminal elimination half-life: 13–19 hours (mean 16 h); clinical context: supports once-daily dosing for estrogen replacement.
Renal (primarily as glucuronide conjugates, 70-80%); fecal (biliary excretion of conjugates, 20-30%); <5% unchanged
Renal: ~50% as glucuronide and sulfate conjugates; fecal: ~30% via enterohepatic recirculation; biliary: ~20%.
Category C
Category C
Estrogen
Estrogen